SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/A46864EB7ED22823568DD36F9CA52C277943CC6EA214617E0E1850AD26FC5AF81CE2D136B1C0DE634E6AB39B47F1C0DE>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/A46864EB7ED22823568DD36F9CA52C277943CC6EA214617E0E1850AD26FC5AF81CE2D136B1C0DE634E6AB39B47F1C0DE
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/A46864EB7ED22823568DD36F9CA52C277943CC6EA214617E0E1850AD26FC5AF81CE2D136B1C0DE634E6AB39B47F1C0DE
http://www.w3.org/2000/01/rdf-schema#comment
"unlike an anti-VEGFR-3 Mab (mF4-31C1) DC101 was not capable of eliminating either tumor lymphangiogenesis or lymphogenous metastasis (60 % reduction of lymph node metastasis by DC101 vs 95 % by mF4-31C1)."
xsd:string
http://purl.uniprot.org/uniprot/#_6393B59B8AB7FCA44848B8108FCDA5D10325357CE57E887850701EB5B1CB2D5D5C0CDCDDA2295479148F9F61463A2BFC
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/A46864EB7ED22823568DD36F9CA52C277943CC6EA214617E0E1850AD26FC5AF81CE2D136B1C0DE634E6AB39B47F1C0DE
http://purl.uniprot.org/uniprot/B5A927
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A46864EB7ED22823568DD36F9CA52C277943CC6EA214617E0E1850AD26FC5AF81CE2D136B1C0DE634E6AB39B47F1C0DE
http://purl.uniprot.org/uniprot/#_B5A927-mappedCitation-23591595
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/A46864EB7ED22823568DD36F9CA52C277943CC6EA214617E0E1850AD26FC5AF81CE2D136B1C0DE634E6AB39B47F1C0DE